121,867 Shares in Intuitive Surgical, Inc. $ISRG Acquired by Nykredit A S

Key Points

• Nykredit A S acquired 121,867 shares of Intuitive Surgical in the second quarter, valued at approximately $48.5 million. Institutional investors collectively own 83.64% of the company.
• Insiders sold 12,370 shares worth approximately $4.9 million during the last quarter, including sales by EVP Gary Loeb and Director Amy Ladd under pre-arranged Rule 10b5-1 plans.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $508.68. Intuitive Surgical recently beat quarterly earnings and revenue estimates, reporting 18.4% year-over-year revenue growth.

Nykredit A S purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 121,867 shares of the medical equipment provider's stock, valued at approximately $48,464,000.

A number of other large investors have also modified their holdings of ISRG. Main Street Group LTD acquired a new position in shares of Intuitive Surgical during the first quarter worth $30,000. Compass Financial Management LLC acquired a new position in Intuitive Surgical in the second quarter valued at approximately $30,000. Vermillion Wealth Management Inc. boosted its holdings in Intuitive Surgical by 58.1% in the first quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 25 shares in the last quarter. Motiv8 Investments LLC purchased a new position in Intuitive Surgical during the 4th quarter worth approximately $34,000. Finally, Evergreen Advisors LLC acquired a new position in Intuitive Surgical during the first quarter worth approximately $35,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Insider Activity

In other news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total transaction of $151,600.00. Following the sale, the executive vice president owned 5,320 shares in the company, valued at $2,016,280. This trade represents a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Ladd sold 72 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $393.10, for a total transaction of $28,303.20. Following the completion of the transaction, the director directly owned 179 shares of the company's stock, valued at approximately $70,364.90. The trade was a 28.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,370 shares of company stock worth $4,891,989 in the last quarter. Insiders own 0.60% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ISRG. KeyCorp reissued an "overweight" rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. The Goldman Sachs Group set a $558.00 price objective on shares of Intuitive Surgical in a research note on Wednesday, May 27th. Citigroup reduced their target price on shares of Intuitive Surgical from $590.00 to $500.00 and set a "buy" rating for the company in a report on Friday, July 17th. BTIG Research reissued a "buy" rating and set a $469.00 price target on shares of Intuitive Surgical in a report on Tuesday, September 8th. Finally, Leerink Partners dropped their price target on Intuitive Surgical from $573.00 to $454.00 and set an "outperform" rating on the stock in a research report on Friday, July 17th. Twenty-two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $508.68.

Intuitive Surgical Stock Up 2.6%

Shares of NASDAQ:ISRG opened at $393.33 on Friday. Intuitive Surgical, Inc. has a 52-week low of $328.57 and a 52-week high of $603.88. The stock's fifty day simple moving average is $372.69 and its 200-day simple moving average is $419.71. The company has a market capitalization of $138.96 billion, a P/E ratio of 45.06, a P/E/G ratio of 2.89 and a beta of 1.47.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, beating the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The firm had revenue of $2.89 billion during the quarter, compared to analyst estimates of $2.83 billion. During the same period in the prior year, the firm posted $1.81 earnings per share. The business's quarterly revenue was up 18.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc is a medical technology company that develops and manufactures robotic-assisted surgical systems and related products. Its technology is designed to support surgeons during minimally invasive procedures by providing enhanced visualization, instrument control and dexterity.

The company's principal product is the da Vinci Surgical System, which is used across a range of specialties, including general surgery, urology, gynecology, cardiothoracic surgery and other procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.